Summary: Grepa‰oxacin (GPFX) is a new quinolone antibiotic (NQ) which is highly distributed to the lung and other tissues. In the present study, to characterize the distribution mechanism of GPFX to the lung, the uptake of GPFX by isolated rat lung cells was examined in vitro. GPFX was rapidly taken up by the cells, and the uptake reached a steady-state within 5 min. The cell-to-medium concentration ratio at equilibrium was 56.8±1.9 mL W mg protein, which was much higher than the cellular volume. GPFX uptake consisted of a saturable component (K m : 264±181 mM, V max : 2.94±2.33 nmol W min W mg protein) and a nonsaturable component (Pdif: 7.04±2.17 mL W min W mg protein). The uptake of GPFX was reduced in the presence of ATP-depletors (FCCP and Rotenone) and by the replacement of sodium with choline in the medium, suggesting that GPFX uptake is at least partially mediated by an Na ＋ -and energy-dependent process. GPFX uptake tended to be reduced in the presence of other NQs such as levo‰oxacin, lome‰oxacin and spar‰oxacin, but was only minimally aŠected by the substrates of several uptake mechanisms already identiˆed in the liver and kidney such as taurocholate, p-aminohippurate, L-carnitine and tetraethylammonium. These results suggested that GPFX is taken up by the lung partially via carrier-mediated transport system(s), distinct from the identiˆed transporters, and such active transport systems may at least partially account for the e‹cient distribution of GPFX to the lung.
Introduction
Grepa‰oxacin (GPFX), a new quinolone antibiotic (NQs) has been reported to be highly distributed in a variety of tissues compared with other NQs. [1] [2] [3] [4] This pharmacokinetic property is a great advantage for the treatment of certain types of infectious diseases. We have investigated the key factors governing the tissue distribution of GPFX during infusion and after bolus injection. At the steady-state, the tissue-to-blood concentration ratio (Kp) of GPFX was highest in the lung and there was a good correlation with the phosphatidylserine (PhS) content in each tissue, suggesting that PhS is the major determinant of the tissue distribution of GPFX. 5) Tamai et al. have reported that GPFX distribution to the brain after bolus injection is restricted by an active eOEux transport mediated by P-glycoprotein. 6) We have also observed active eOEux of GPFX mediated by multidrug resistance associated protein 1 in certain tissues such as the heart and kidney. Thus, transportermediated eOEux from tissues is also an important factor aŠecting GPFX distribution. However, the in‰ux mechanism(s) of GPFX to the lung has not yet been identiˆed. Active in‰ux mechanisms for certain types of drugs have been proposed, especially in the liver and kidney. In fact, we have already proposed the involvement of active transport mechanisms in the hepatocellular uptake of GPFX. 7) Ito et al. also suggested a speciˆc transport system for the renal distribution of GPFX. 8) In contrast, limited information is available on carriermediated transport in the lung. It should be noted that the antibiotics HSR-903 and clarithromycin have been reported to be taken up by carrier-mediated active trans-port into isolated rat lung cells 9, 10) although the active transport system(s) has not yet been fully characterized. Considering that lung is one of the most important pharmacological targets for antibiotics, characterization of the uptake mechanisms to the lung will provide useful information to help with the development of new drugs e‹ciently delivered to the lung.
Consequently, to characterize the distribution mechanism of GPFX to the lung, GPFX uptake by isolated rat lung cells in vitro was evaluated in the present study. Preparation of isolated rat lung cells: Male Sprague-Dawley rats were purchased at 6 or 7 weeks of age from Charles River Japan Ltd. Isolated lung cells were prepared using a minor modiˆcation of the method of Dawson et al. 11) Brie‰y, rats were anesthetized with ketamine, the pulmonary artery was cannulated, and the lung was perfused with Krebs-Henseleit buŠer (KHB, pH 7.4) containing 2.5z BSA and 5 mM glucose. The trachea was then cannulated and perfused for 20 min with Ca 2＋ , Mg 2＋ -free HBSS (pH 7.4) containing 0.1z protease type VIII and 1mM EDTA. The lung was then minced, and the lung cells were puriˆed by centrifugation at 49 C and 400×g for 5 min. The resultant pellets were suspended in KHB and used for the uptake study. The composition of the sodium-free buŠer was the same as KHB, except that the sodium chloride was replaced isotonically with choline chloride and sodium bicarbonate was replaced with choline bicarbonate. All experiments were performed in accordance with the Guidelines for Animal Care and Use in Otsuka Pharmaceutical Co. Ltd.
Materials and Methods

Materials
Uptake study: Uptake of [ 14 C]-GPFX was initiated by adding the prewarmed ligand solution (0.05 mL) to the cell suspension (ˆnal 0.48 mg W mL) after preincubating the cell suspension at 379 C for 3 min. At the designated times after incubation at 379 C, the uptake was terminated by separating the cells from the medium by centrifugalˆltration. 12) Brie‰y, 500 mL aliquots were placed into centrifuge tubes containing silicone oil (density 1.006, Dow Corning Toray Co. Ltd, Tokyo).
The sample was then centrifuged at 3,000×g for 15 sec. After centrifugation, the medium on the silicon oil layer was transferred to scintillation vials, and the centrifuge tubes were frozen at -809 C. Then, the frozen centrifuge tubes were cut and the pellets of lung cells were transferred to scintillation vials. The lung cells were dissolved with 1 mL of tissue solubilizer Biomerit (Nacalai Tesque, Inc., Kyoto, Japan) at 509 C for 30 min. The lysate was neutralized with 1 mL of adjustment solution Biomerit (Nacalai Tesque, Inc.), and then scintillation cocktail (Hionic-Fluor, Packard, Meriden, CT) was added. The radioactivities of the medium and lung cells were measured using a liquid scintillation counter (LSC-1050 and LSC-3500, Aloka). The concentration of [ 14 C]-GPFX was 10 mM except for the concentration-dependence study. To prepare the cell suspension at designed protein concentration for uptake study, protein concentrations in the lung cell suspensions were determined by the Lowry method, 13) using a protein assay kit (Bio-Rad, Hercules, CA) with bovine serum albumin as a standard.
The time-course of [ 14 C]-GPFX uptake was plotted as a distribution volume ( mL W mg protein) that was obtained by dividing the amount taken up by its concentration in the medium. The initial uptake velocity of [ 14 C]-GPFX was calculated using a linear regression of points between 10 and 30 sec. The kinetic parameters for [ 14 C]-GPFX uptake were calculated using the following equation:
where V0 is the initial uptake rate of the drug (pmol W min W mg protein), S is the drug concentration in the medium ( mM), Km is the Michaelis-Menten constant ( mM), V max is the maximum uptake rate (nmol W min W mg protein) and Pdif is the nonspeciˆc uptake clearance ( mL W min W mg protein). The above equation wasˆtted to the uptake data sets by an iterative nonlinear leastsquares method using a WinNonlin program ver. 1.5 (Scientiˆc Consulting, Inc., Apex, NC) to obtain estimates of the kinetic parameters. In the inhibition study, a mixture of [ 14 C]-GPFX and each drug was added to the cell suspension simultaneously, except for the ATPdepletors such as FCCP and rotenone, which were added at the start of preincubation.
Statistical Analysis: Statistical analysis of the experimental data was performed using Dunnett's test (SAS version 8.1 computer software). Pº0.05 and Pº0.01 were regarded as statistically signiˆcant.
Results
Time-course and concentration-dependence of [ 14 C]-GPFX uptake by isolated rat lung cells: The time-prole of the uptake of GPFX by isolated rat lung cells is Fig. 1A . GPFX was rapidly taken up by the cells, and its uptake reached equilibrium within 5 min. The GPFX uptake at equilibrium was 56.8±1.9 mL W mg protein. The initial uptake of GPFX at various substrate concentrations was obtained from the diŠerence between the uptake at 10 and 30 sec. Uptake of GPFX exhibited saturable and nonsaturable components (Fig. 1B) . The kinetic parameters, Km and Vmax, of saturable uptake were 264±181 mM and 2.94±2.33 nmol W min W mg protein, respectively and the uptake clearance (P dif ) of a nonsaturable component was 7.04 ±2.17 mL W min W mg protein. The contribution of the saturable component to the total GPFX uptake was approximately 50z under linear conditions.
EŠects of temperature, sodium, ATP-depletors, other NQs and substrates of several transport systems identied in liver and kidney on the initial uptake of [
C]-GPFX:
The initial uptake of GPFX at 279 C and 09 C was 40z and 4z of that at 379 C, respectively ( Table 1) . GPFX uptake was reduced in the presence of ATP-depletors (FCCP and Rotenone) and by replacement of sodium in the medium by choline ( Table 1) . The initial uptake of GPFX tended to be reduced in the presence of a 1 mM concentration of other NQs although the eŠect was not signiˆcant ( Table 2) . However, TCA, PAH, L-carnitine and TEA, substrates of the known transporters, had only a minimal eŠect on GPFX uptake ( Table 2) .
Discussion
Considering that the lung is one of the most important pharmacological targets for antibiotics, it is important to characterize the distribution mechanism of these drugs to the lung. In the present study, we have examined uptake of GPFX by isolated lung cells since GPFX exhibits greater distribution to the lung and other tissues, compared with other NQs. GPFX was rapidly taken up by isolated rat lung cells, its uptake at steady state being approximately 55 mL W mg protein (Fig. 1) . This can be expressed as 44.4 mL W 10 7 cells when we consider that 1 mg protein corresponds to 1.24×10 7 cells (observed value in the present study). This value was much higher than the reported cellular volume (0.97 mL W 10 7 cells), 9) indicating that GPFX is highly distributed to lung cells. Thus, marked GPFX distribution was reproduced in this isolated lung cell system. The following experimentalˆndings obtained in the present study support the hypothesis that GPFX uptake into lung cells is partially mediated by active transport systems: (i) Kinetic analysis showed that GPFX uptake consisted of a saturable component (Km 264 mM) as well as a nonsaturable one (Fig. 1) . GPFX uptake is (ii) temperature-dependent, (iii) ATP-dependent and (iv) tended to be reduced in the presence of other NQs ( Table 1, 2) . By comparing Vmax W Km with Pdif, the saturable component was calculated to account for approximately half of the total GPFX uptake. This was compatible with the presentˆnding that the reduction in the presence of ATP depletors was also half of the control (Table 1) . Thus, GPFX uptake is not mediated by a single transport component, but, possibly, by multiple transport mechanisms. The clinical therapeutic concentration of GPFX is considered to be 2-5 mM, 14) and its human plasma unbound partition ratio (fp) is 0.5.
2) As a result, the unbound plasma concentration will be less than 2.5 mM, which is much lower than the Km (264 mM) estimated in the present uptake study using isolated rat lung cells. Therefore, in view of the similarity of the transporter a‹nity in humans and rats, the active transport was considered not to be saturated and, hence, GPFX will be actively taken up by the lung at clinical doses.
It is possible that the Na ＋ -independent uptake may also represent saturable transport systems. A further transport study under Na ＋ -free conditions will enable us to examine the validity of this hypothesis. It should be noted that the GPFX uptake was much more clearly reduced at 09 C (3.4z of control, Table 1 ). Although this can be explained if we accept that diŠusion and W or membrane ‰uidity must be changed at 09 C, aŠecting the simple diŠusion process, we cannot rule out the possibility of the existence of another temperature-sensitive transport process which can be identiˆed by further analysis.
The alveolae consist of type I sequamous alveolar cells (¿95z area) and type II large alveolar cells. Type I alveolar cells are thought to be involved in the transport function. Dawson et al., 11) have reported that an isolated lung cell suspension consists of type I and type II alveolar cells, in addition, a few endothelial cells, interstitial cells and macrophage, although the numbers of these cells were not measured in present study. The direction of transport cannot be speciˆed in isolated cells because of the absence of polarity. Therefore, further studies are needed toˆnally demonstrate the directional transport of GPFX from the blood side into the lung cells, using lung perfusion studies and W or polarized cell culture systems. It is also possible that the energy-independent and non-saturable uptake of GPFX observed in isolated lung cells may be due to the mixture of several kinds of cells and W or the mixture of directional transport. However, it should be noted that, in the isolated rat lung perfusion study, HSR-903, another NQ exhibited saturation in its distribution into the lung at a perfusate concentration very close to the Km estimated in the isolated lung cell study, 9) indicating that there is a saturable mechanism in the lung controlling uptake from the circulating blood. On the other hand, the distribution of GPFX in the lung single-pass experiment did not show a clear concentration dependence.
5) The dose of GPFX must be diluted by a large circulating blood ‰ow rate (approximately 180 mL W min W kg). The actual plasma concentration is not clear, as it is further reduced by plasma protein binding (fp 0.6).
2) Therefore, to understand the discrepancy, we have to perform further comparative analysis of the actual free concentration in vivo and the Km in the isolated lung cell study.
The characteristics of the uptake mechanism(s) for GPFX are similar to those reported for the uptake by isolated rat lung cells of HSR-903, another NQ that has a high distribution to the lung. 9) For example, the uptake of GPFX ( Table 1 ) and HSR-903 9) exhibits Na ＋ -dependence. Moreover, the uptake of HSR-903 is also composed of both saturable and nonsaturable components, and inhibited by 500 mM GPFX and spar‰oxa-cin. 9) Thus, it can be hypothesized that NQs are taken up into the lung cell by common active transport system(s). However, the characteristics of the transport system for GPFX was not compatible with those of transporters already identiˆed in the liver and kidney for organic anions and cations because the GPFX uptake was only minimally aŠected by TCA, PAH, L-carnitine and TEA ( Table 2) , substrates of organic anion transporting polypeptide, organic anion transporter, organic cation W carnitine transporter and organic cation transporter families. [15] [16] [17] In conclusion, carrier-mediated active transport system(s) are partially involved in GPFX uptake by the lung and contribute to the high distribution of this compound to the lung.
